Regado’s anticoagulant shows promise in Phase I studies
The data showed that RB006 completely inhibited the activity of factor IXa, a protein essential to blood clotting, and RB006’s activity was rapidly and safely reversed by RB007
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Data from two international, double-blind, randomized, placebo-controlled Phase III clinical trials in patients with hyperphenylalaninemia due to phenylketonuria show that treatment with sapropterin reduces blood phenylalanine levels and